FRI0296 The Optimal Modified Rodnan Skin Score To Predict Skin Progression over One Year Differs between Autoantibody Subsets

BackgroundThere are muliple potential therapeutic a gents under development for sstemic sclerosis (SSc). Given that SSc is uncommon, there is interest in cohort enrichment to maximize the potential of identifying a drug effect, One area of interest is a modified Rodnan skin score (mRSS) cut-off as an inclusion criterion in early diffuse SSc trials. Autoantibody profiles of SSc patients vary by geographical region. Given that the mRSS differs between autoantibody groups and that many trials are multinational, it is important to understand the differences in mRSS patterns between autoantibodies to choose optimal mRSS cut-off points that facilitates enrichment for patients likely to develop skin progression.ObjectivesWe sought to determine the baseline mRSS to maximally predict progressive skin involvement over one year in US patients with early diffuse SSc, and assess if this differed by autoantibody.MethodsWe examined a US single-center cohort of prospectively followed early diffuse SSc patients seen for an initial visit between 1980 and 2014. To reflect modern early diffuse SSc clinical trial design, early was defined as